KALV — Kalvista Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$27.00
+$0.00 (+0.00%)
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ. It is led by Benjamin L. Palleiko, based in 200 Crossing Boulevard, Framingham, MA, United States, 01702, with about 275 employees. As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. Revenue was up 878.6% from 2025-07-31 to 2025-09-30. KALV currently screens at market cap $1.44B.
Use this KALV page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KALV quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KALV SEC filings page. Lician reads the product cache first so this HTML stays unique to Kalvista Pharmaceuticals Inc even when a live quote feed is slow.
About Kalvista Pharmaceuticals Inc
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
KALV Key Statistics
Market Cap
$1.44B
Volume
4.26M
Previous Close
$27.00
Day Range
$26.98 – $27.00
P/B Ratio
49.03
EPS
-$3.69
Revenue
$0.00
Net Income
-$183.44M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
275
KALV Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0.00 | $50.00M |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$183.44M | -$126.64M |
| EPS (Diluted) | -$3.69 | -$3.44 |
Total Assets
$250.77M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$131.62M
Operating Cash Flow
-$152.91M
Free Cash Flow
$0.00
Kalvista Pharmaceuticals Inc Company Information
- CEO & Director
- Benjamin L. Palleiko
- Headquarters
- 200 Crossing Boulevard, Framingham, MA, United States, 01702
- Website
- www.kalvista.com
- Phone
- 857 999 0075
- IPO / Founded
- 2015-04-09
- Sector
- Healthcare
- Industry
- Biotechnology